HRSA doubles 340B contract pharmacy audits, reviewing 47 entities
Issue
HRSA has doubled 340B audits of contract pharmacy arrangements, with 47 covered entities under review in the first quarter of 2026. Common problems are duplicate discounts, weak patient eligibility checks and missing pharmacy agreements.
Health centers need real-time eligibility checks and full audit trails, or they risk repayment and suspension.
Key points
- HRSA doubled 340B audits, with 47 covered entities under review in the first quarter of 2026.
- Common problems: duplicate discounts, weak eligibility checks and missing pharmacy agreements.
- Violations can mean repaying the program and suspension.
- Show real-time eligibility checks, correct split billing and full audit trails.
Sources for this story
HRSA Office of Pharmacy AffairsPart of
- 340B drug pricing
HRSA audits and repayment
Sources for your board packet
This story's source plus 4 related stories and their sources, ready to print for your team or board.
The newsletter is paused right now. Sign up and you will get it when it starts again.
Free. Unlocking the packet subscribes you to Intel Brief. You'll also get a short welcome series and the occasional product update. You'll be subscribed right away, with no confirmation email. Unsubscribe with one click in any issue. If you unsubscribed before, we won't re-add you. We never sell your email. You can open each source above without an email.
FQHC Talent. (2026, February 15). HRSA doubles 340B contract pharmacy audits, reviewing 47 entities. Source: HRSA Office of Pharmacy Affairs. Retrieved November 22, 2026, from https://www.fqhctalent.com/intel/340b-audit-wave-contract-pharmacy-2026